Adicet Bio (STU:1IJA) Debt-to-Equity : 0.08 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Debt-to-Equity?

Adicet Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €3.06 Mil. Adicet Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €15.38 Mil. Adicet Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €238.10 Mil. Adicet Bio's debt to equity for the quarter that ended in Mar. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Adicet Bio's Debt-to-Equity or its related term are showing as below:

STU:1IJA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.09 Max: 0.2
Current: 0.08

During the past 6 years, the highest Debt-to-Equity Ratio of Adicet Bio was 0.20. The lowest was 0.07. And the median was 0.09.

STU:1IJA's Debt-to-Equity is ranked better than
63.58% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs STU:1IJA: 0.08

Adicet Bio Debt-to-Equity Historical Data

The historical data trend for Adicet Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Debt-to-Equity Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.20

0.07

0.12

Adicet Bio Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.09	0.10	0.11	0.12	0.08

Competitive Comparison of Adicet Bio's Debt-to-Equity

For the Biotechnology subindustry, Adicet Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Debt-to-Equity falls into.

Adicet Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Adicet Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.954	+	16.234)	/	156.05
	=	0.12

Adicet Bio's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.056	+	15.377)	/	238.1
	=	0.08

Adicet Bio (STU:1IJA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Adicet Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (STU:1IJA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (STU:1IJA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (STU:1IJA) Headlines

No Headlines